For the first time “AstraZeneca” admits that its vaccine against Corona may cause blood clots

AstraZeneca acknowledged for the first time that its Corona vaccine, which carries the brand Covishield, may cause rare side effects, including blood clots and low platelets.

Covishield was developed by the British-Swedish company in collaboration with the University of Oxford in the United Kingdom, and produced by the Serum Institute of India, and has been widely distributed in more than 150 countries, including Britain and India.

Some studies conducted during the pandemic found that the vaccine was 60 to 80 percent effective in protecting against the mutant coronavirus. However, research has since found that Covishield can cause some people to develop blood clots, which can be fatal.

A class action lawsuit filed in the United Kingdom alleged that the vaccine led to deaths and serious injuries and sought damages of up to 100 million pounds for about 50 victims.

One complainant claimed that the vaccine caused him permanent brain injury after he developed a blood clot that prevented him from working.

While AstraZeneca disputed these claims, it admitted for the first time in a court document that the vaccine could “in very rare cases, cause thrombosis with thrombocytopenia syndrome, which is characterized by blood clots and low platelet counts in humans.”

The World Health Organization confirmed that Covishield could have life-threatening side effects, stating that “a very rare adverse event called thrombosis with thrombocytopenia syndrome, which includes unusual and severe blood clotting events associated with a low platelet count, has been reported after vaccination with this.” the vaccine".